Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK ...

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

Bireociclib plus fulvestrant significantly improved progression-free survival and response rates in advanced HR-positive ...

WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central ...

The MarketWatch News Department was not involved in the creation of this content. Multiple long-term follow-up studies confirm BRUKINSA's superior efficacy and favorable tolerability versus ibrutinib ...

Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...

Adding lenvatinib to pembrolizumab improved PFS (6.2 vs 2.8 months; HR 0.64) and ORR (46.1% vs 25.4%) versus pembrolizumab ...